MV14
MV14 is a small-molecule NO donor that exhibits selective antiproliferative activity against bladder cancer cells. MV14 releases NO, causing DNA double-strand damage, inhibiting the NF‑κB pathway, and downregulating the apoptosis-inhibitory protein Survivin. MV14 interferes with the cell cycle and promotes tumor cell apoptosis. MV14 attenuates tumor-associated histopathological changes, urothelial destruction, and stromal invasion in the BBN (HY-W755252)-induced mouse bladder cancer model, and reduces PCNA levels in bladder tumor tissue while increasing active caspase-3. MV14 can be used for research on bladder cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2377778-85-1
- 分子式: C15H19N3O7S
- 分子量:385.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
MV14 is a small-molecule NO donor that exhibits selective antiproliferative activity against bladder cancer cells. MV14 releases NO, causing DNA double-strand damage, inhibiting the NF‑κB pathway, and downregulating the apoptosis-inhibitory protein Survivin. MV14 interferes with the cell cycle and promotes tumor cell apoptosis. MV14 attenuates tumor-associated histopathological changes, urothelial destruction, and stromal invasion in the BBN (HY-W755252)-induced mouse bladder cancer model, and reduces PCNA levels in bladder tumor tissue while increasing active caspase-3. MV14 can be used for research on bladder cancer[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RT-4 | IC50 |
0.20 μM
|
Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay.
Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay.
|
42790168 |
| RT-4 | IC50 |
0.32 μM
|
Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay.
Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay.
|
42790168 |
| RT-4 | IC50 |
0.34 μM
|
Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay.
Cytotoxicity against human RT4 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay.
|
42790168 |
| T-24 | IC50 |
0.89 μM
|
Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay.
Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 24 hrs by MTT assay.
|
42790168 |
| T-24 | IC50 |
0.73 μM
|
Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay.
Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 48 hrs by MTT assay.
|
42790168 |
| T-24 | IC50 |
0.69 μM
|
Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay.
Cytotoxicity against human T24 bladder cancer cells assessed as viability reduction incubated 72 hrs by MTT assay.
|
42790168 |
体外実験
Anti-cancerCell Cycle RegulationInnate ImmunityCytokines & ChemokinesOxidative StressOthers
Anti-cancer
MV14 (0.09-12.5 μM; 24-72 h) reduces the viability of RT4, T24, and 253J bladder cancer cells, with IC50 values in the submicromolar range over 24-72 h, whereas the IC50 value in SV-HUC-1 non-malignant urothelial cells is approximately 1.06-1.08 μM[1].
MV14 (0.19-6.25 μM; 24 h) exerts antiproliferative activity against T24 and 253J bladder cancer cells that is partly contributed by NO release, with T24 cells showing higher sensitivity to NO scavenging[1].
MV14 (0.39-3.13 μM; 24 h) inhibits the migration of T24 bladder cancer cells[1].
MV14 (5-10 μM; 3 h) induces concentration-dependent γ-H2AX DNA damage in T24 and 253J bladder cancer cells, and NO release is involved in this effect[1].
MV14 (0.39-1.56 μM (T24); 0.09-0.39 μM (253J); 24 h) reduces nuclear survivin in T24 and 253J bladder cancer cells[1].
MV14 (1.56-3.13 μM; 24 h) reduces total survivin protein in T24 bladder cancer cells[1].
MV14 (0.19-6.25 μM; 24 h) exerts antiproliferative activity against T24 and 253J bladder cancer cells that is partly contributed by NO release, with T24 cells showing higher sensitivity to NO scavenging[1].
MV14 (0.39-3.13 μM; 24 h) inhibits the migration of T24 bladder cancer cells[1].
MV14 (5-10 μM; 3 h) induces concentration-dependent γ-H2AX DNA damage in T24 and 253J bladder cancer cells, and NO release is involved in this effect[1].
MV14 (0.39-1.56 μM (T24); 0.09-0.39 μM (253J); 24 h) reduces nuclear survivin in T24 and 253J bladder cancer cells[1].
MV14 (1.56-3.13 μM; 24 h) reduces total survivin protein in T24 bladder cancer cells[1].
Anti-cancer
Cell Cycle Regulation
MV14 (0.78-3.13 μM (T24); 0.19-0.78 μM (253J); 24 h) induces G2/M phase accumulation in T24 cells and S phase arrest in 253J bladder cancer cells[1].
Innate Immunity
Cytokines & Chemokines
Oxidative Stress
MV14 (100 μM), as an NO donor, exhibits sustained release kinetics, being detectable from 15 min and persisting until 24 h[1].
Others
MV14 shows no mutagenicity against Salmonella typhimurium TA97a, TA98, TA100, TA1535, and Escherichia coli WP2 uvrA at concentrations of 1-100 μg/plate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[1]
-
Cell Line:RT4, T24, and 253J human bladder cancer cell lines and SV-HUC-1 non-malignant urothelial cells
-
Concentration:RT4: 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
T24: 0.09, 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
253J: 0.09, 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM
SV-HUC-1: 0.39, 0.78, 1.56, 3.13, 6.25, 12.50 μM -
Incubation Time:24, 48, and 72 h
-
Result:Reduced viability of RT4, T24, and 253J bladder cancer cells with submicromolar IC50 values across 24-72 h, including 0.25 μM in 253J at 72 h, while SV-HUC-1 non-malignant urothelial cells show IC50 values of approximately 1.06-1.08 μM.
Cell Proliferation Assay[1]
-
Cell Line:T24 and 253J bladder cancer cells
-
Concentration:0.19, 0.39, 0.78, 1.56, 3.13, 6.25 μM
50 μM (Hb (HY-P2995)) -
Incubation Time:1 h (Hb pre-exposure); 24 h (MV14 exposure)
-
Result:Reduced cell proliferation in a concentration‑dependent fashion. Diminished antiproliferative potency in both T24 and 253J cells upon 50 μM Hb treatment, with a more pronounced effect observed in T24 cells. Partially recovered inhibitory activity at the highest tested concentrations in 253J cells.
Cell Migration Assay [1]
-
Cell Line:T24 bladder cancer cells
-
Concentration:0.39, 0.78, 1.56, 3.13 μM
-
Incubation Time:24 h
-
Result:Reduced wound‑closure efficiency in a concentration‑dependent manner, lowering wound‑closure rates to 67 % at 0.39 μM and 21 % at 3.13 μM.
Suppressed T24 cell migration, producing stronger inhibitory effects at 0.78 μM, 1.56 μM and 3.13 μM.
Cell Cycle Analysis[1]
-
Cell Line:T24 and 253J bladder cancer cells
-
Concentration:0.78, 1.56, 3.13 μM (T24)
0.19, 0.39, 0.78 μM (253J) -
Incubation Time:24 h
-
Result:Exhibited dose‑dependent G0/G1‑phase reduction and G2/M‑phase elevation in T24 cells, indicating DNA‑damage‑related checkpoint activation and potential premitotic arrest.
Produced dose‑dependent G0/G1‑phase decline and marked S‑phase accumulation with unaltered G2/M fraction in 253J cells, pointing to replicative stress and S‑phase cell retention.
Immunofluorescence[1]
-
Cell Line:T24 and 253J bladder cancer cells
-
Concentration:5, 10 μM
100 μM (Hb pretreatment) -
Incubation Time:3 h
-
Result:Induced concentration-dependent γ-H2AX DNA damage in T24 and 253J bladder cancer cells.
Immunofluorescence[1]
-
Cell Line:T24 and 253J bladder cancer cells
-
Concentration:0.39, 0.78, 1.56 μM (T24)
0.09, 0.19, 0.39 μM (253J) -
Incubation Time:24 h
-
Result:Reduced nuclear survivin in T24 and 253J bladder cancer cells, reaching approximately 50% of control at 1.56 μM in T24 and showing greater sensitivity in 253J at 0.09-0.39 μM.
Western Blot Analysis[1]
-
Cell Line:T24 bladder cancer cells
-
Concentration:1.56, 3.13 μM
-
Incubation Time:24 h
-
Result:Reduced total survivin protein in T24 bladder cancer cells at 1.56 and 3.13 μM after 24 h.
体内実験
Anti-cancerApoptosis
Anti-cancer
Apoptosis
MV14 (1 mg/mL; 100 μL; intravesical administration; once weekly; for four consecutive weeks (weeks 17-21)) attenuates BBN (HY-W755252)-induced histopathological changes in bladder tumors and reduces survivin and PCNA levels while increasing active caspase-3 in C57BL/6 tumor-bearing mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, received 0.05% BBN (HY-W755252) in drinking water ad libitum for 16 weeks)[1]
-
Dosage:1 mg/mL; 100 μL per intravesical instillation
-
Administration:intravesical; once weekly; four consecutive weeks (weeks 17-21)
-
Result:Attenuated tumor-associated histopathological alterations in BBN-induced bladder tumors, with less urothelial disruption and less pronounced stromal invasion than vehicle-treated tumor-bearing mice.
Tumors showed urothelial cell hyperplasia with lower-grade undifferentiation and dysplasia toward the lamina propria, moderate anisocytosis and anisokaryosis, nuclear atypia, fewer binucleated cells, and fewer mitotic figures than vehicle-treated tumors.
Reduced survivin levels and decreased PCNA-positive cells in tumor tissue, while increasing active caspase-3-positive cells.
Related Protocols :
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- PCNA Immunodetection Proliferation Assay
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Cell invasion
- Cell Viability Determination by MTT Colorimetric Assay
化学情報
-
CAS 番号 2377778-85-1
-
分子量 385.39
-
分子式 C15H19N3O7S
-
SMILES
[O-][N+]1=C(S(=O)(C2=CC=CC=C2)=O)C(OCCNC(OC(C)(C)C)=O)=NO1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
モル濃度計算機
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
希釈計算機
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MV14 関連分類
HY-190489 関連分類
Powered by Bioz